We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

“We are pleased to welcome Jim to Dicerna’s management team,” said Douglas M. Fambrough, Ph.D., chief executive officer of Dicerna. “Jim is a seasoned pharmaceutical executive with a proven skill set in business development, marketing, product development and strategic planning. We look forward to leveraging his unique expertise as we continue to innovate and accelerate our business development and partnering strategy focused on our Dicer Substrate Technology.”

Mr. Weissman is a life sciences executive with extensive international management experience in biotech and pharmaceutical general management, product development, licensing, business development, marketing and M&A activities. He joins Dicerna from MannKind Corporation (Nasdaq: MNKD), where he was vice president of business development, responsible for leading the company’s activities related to licensing, new products and strategic planning. Prior to MannKind, Mr. Weissman held leadership positions in both business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, most recently as senior director of marketing. In this position, Mr. Weissman was responsible for the sales, profit and strategic targets for the company’s specialty products, including CNS, endocrinology, ophthalmology, oncology and diversified portfolios. Mr. Weissman holds a Bachelor of Science from Bates College in Maine.

“There continues to be strong interest and progress in the research and development of RNAi therapies, and Dicerna’s Dicer Substrate Technology provides differentiation and offers significant advantages over other RNAi approaches,” said Mr. Weissman. “I look forward to helping Dicerna continue to execute on its business strategy and further the research and development efforts utilizing the company’s unique platform.”